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Potassium channelMembrane lipid rafts are distinct plasma membrane nanodomains that are enriched with cholesterol,
sphingolipids and gangliosides, with occasional presence of saturated fatty acids and phospholipids containing
saturated acyl chains. It is well known that they organize receptors (such as Epithelial Growth Factor Receptor),
ion channels and their downstream acting molecules to regulate intracellular signaling pathways. Among them
are Ca2+ signaling pathways, which are modiﬁed in tumor cells and inhibited upon membrane raft disruption.
In addition to protein components, lipids from rafts also contribute to the organization and function of Ca2+
signaling microdomains. This article aims to focus on the lipid raft KCa/ClCa/Ca2+ channel complexes that
regulate Ca2+ and EGFR signaling in cancer cells, and discusses the potential modiﬁcation of these complexes
by lipids as a novel therapeutic approach in tumor development. This article is part of a Special Issue entitled:
Membrane channels and transporters in cancers.
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Membrane lipid rafts are distinct plasma membrane nanodomains
that are enriched with cholesterol, sphingolipids and gangliosides,
with occasional presence of saturated fatty acids and phospholipids
containing saturated acyl chains. In some rafts there are very high
amount of ceramides instead of cholesterol [1,2]. It is well known that
they organize receptors (such as Epidermal Growth Factor Receptor,
EGFR), their downstream molecules to regulate intracellular signaling
pathways, which may be inhibited upon membrane raft disruption.
Lipid rafts have been implicated in the regulation of cell proliferation,
apoptosis and cell migration suggesting ﬁrst that alteration of these
nanodomains could be involved in tumor development and second
that their modiﬁcation by lipids may become a novel and attractive
strategy to reduce tumor development.
Lipid rafts provide signaling platforms for several growth factor
receptors such as Human Epidermal growth factor Receptors (HERs),
which are overexpressed in many cancers such as breast (for HER2)
[3] and colon (for EGFR/HER1) [4] and participate in tumor devel-
opment. Interestingly, the activation of EGFR generates intracellu-
lar Ca2+ variations, which by the formation of the Ca2+/CaM
complex also control EGFR activities [5]. Ca2+ homeostasis is regulated
by Ca2+ channels, and during the last decade, these channels and
Ca2+-activated K+ channels (KCa) and Ca2+-activated Cl− channels
(ClCa) were found to be expressed in various tumors. Their physio-
logical function is hijacked by the cancer cell to drive essential bio-
logical functions for tumor development such as cell proliferation
and cell migration [6–10]. For reducing energy consumption and
for the ﬁne regulation of their activities, Ca2+, KCa and ClCa channels
appear to be associated as complexes in cancer cells and contribute
to cancer associated functions such as cell proliferation, cell migration
and the capacity to develop metastases [11]. Thus, we propose that
these complexes are spatially segregated in nanodomains such as lipid
rafts. This particular localisation has been observed for the TRPC1
channelosome [12], and many ion channels are found to be expressed
in lipid rafts [13]. Nevertheless, the speciﬁc localization and regulation
of Ca2+, KCa and ClCa channels alone or as complexes in lipid rafts
need to be addressed in tumor cells.
The role of lipid rafts in tumor cells has been recently reviewed [14].
The present article aims to focus on the lipid raft KCa/ClCa/Ca2+ channel
complexes and EGFR signaling in cancer cells and on the potential
modiﬁcation of these complexes by lipids as a novel therapeutic
approach in tumor development.
2. Lipid rafts
Lipid rafts are deﬁned as nanodomains within the lipid bilayer [2].
Raft domains lead to protein and lipid compartmentalization inside
the plasmamembrane. These highly dynamic structures act as signaling
platforms and coordinate transduction pathways. They are also
involved in endocytosis, protein trafﬁcking and adherens junctions
(see for reviews [15–17]). The lipid raft composition is distinct from
the non-raft domain in cholesterol, glycosphingolipids, sphingolipids,
gangliosides, with occasional presence of saturated fatty acids and
phospholipids containing saturated acyl chains and loss of glycerolipids,
omega 3 fatty acids and phosphatidylethanolamine. In some rafts
there are very high amounts of ceramides instead of cholesterol [1].
Biochemical techniques have allowed to isolate the lipid rafts using
their resistance to solubilization by cold nonionic detergents suchas Triton X-100 [18]. Cholesterol-rich rafts can be separated from non-
raft domains by sucrose gradient centrifugation thanks to their lower
density. More recently, microscopy and spectroscopy techniques have
allowed to directly visualize the lipid raft structure [19], and proteomic
proﬁles of membrane fractions from normal and cancerous human
tissues are henceforth available using labeling mass spectrometry [20].
Two types of lipid rafts can be distinguished: caveolae and non-
caveolae (Fig. 1). Caveolae contains caveolin which is a cholesterol
anchoring protein and a speciﬁc scaffolding protein creating plasma
membrane invagination [21]. In addition to be enriched with cholesterol
and sphingolipids, caveolae also contain a variety of fatty acids highly
enriched with saturated fatty acids, and caveolin-1 (Cav-1) acylated by
palmitic acid and stearic acid [22]. This acetylation of Cav-1 may play a
pivotal role in subcellular location including targeting to caveolae.
Indeed, Cav-1 has been described as formingmobile signaling platforms
within the caveolae by sequestration of multiple proteins through
interaction via the scaffolding domain within the NH2 terminus. In
most cases, the interaction with Cav-1 either maintains the signaling
protein in an inactive state until a stimulus is presented (as observed
for BKCa/KCa1.1, TRPC, and EGFR, see below) or terminates signal
transmission after activation. Caveolae could also form junctional
complexes that couple the plasma membrane and the endoplasmic
reticulum necessary for Ca2+ signaling. For example, this junctional
complex is required for store-operated Ca2+ entry (SOCE) and for the
coupling between BKCa channel and IP3 receptor (IP3R). On the other
hand, non-caveolar rafts are enriched in ﬂotillin. After oligomerization,
ﬂotillin anchors to the plasma membrane via myristoylation and
palmitoylation sites. Unlike caveolae, the microdomains are laterally
mobile within the membrane. They appear to bud into the cell and
form planar lipid rafts, unlike plasma membrane invagination as
observed for caveolar rafts (for review [15]).
The protein and lipid composition of rafts is dramatically altered
in cancer and impacts kinase activity, protein trafﬁcking, adhesion and
apoptosis [17]. Lipid raft-dependent signaling pathways are often
hyperactivated in cancer and implicated in signal deregulation [23].
Oncogenicity of Akt (protein kinase B) arises from the activation of
both proliferative and anti-apoptotic signaling routes. Furthermore,
Akt contributes to tumor progression by promoting cell invasiveness
and angiogenesis [24,25]. Hyperactivated Akt in primary tumors is
considered to be a negative prognostic marker for disease outcome
[26]. Membrane recruitment is crucial for Akt activation and its mem-
brane localization protects Akt from inactivation by phosphatases [25].
This observation is in agreement with the lipid hypothesis that raft
environment controls/regulates protein signaling complexes. Elevated
levels of lipid rafts in cancer cells [27], which are specially enriched
with inositols [28–30], have been related with oncogenesis by promot-
ing overactivation of the Akt signaling pathway [31]. For example Akt
activation is promoted by lipid rafts in colon, melanoma and prostate
cancer cells [32–34].
CD95 is a well-known death receptor, and its proper function is
essential for the elimination of viral or transformed cells [35]. Death
pathway signaling has been related with lipid rafts, including death-
receptor-mediated signaling pathways [36,37]. The partitioning of
both CD95L and CD95 into rafts is necessary for cell death signal trans-
duction [35–39], promoting an efﬁcient CD95–CD95L interaction and
initiating apoptosis [37,39,40]. However, recruitment and aggregation
of CD95 in lipid raft clusters have been shown independent of its ligand
CD95L [41]. In fact CD95 redistribution into lipid rafts can be stimulated
not only by CD95L, but also by drugs that have the potential to mimic a
Fig. 1. Inﬂuence of membrane organization in lipid rafts on localization and subsequent function of membrane proteins. Presence of caveolin or ﬂotillin within lipid rafts confers to
membranes a vesicular or planar spatial organization thus providing to embedded proteins a membrane microenvironment that modiﬁes their function.
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reported not only in leukemic cells, but also in solid tumor cells as colon
cancer [43–45] and cholangiocarcinoma cells [46].
Lipid rafts have also been shown to modulate the actin cytoskeleton
by speciﬁc protein components. The reorganization of the actin cyto-
skeleton after depletion of cell cholesterol affects cell circularity and
plasma membrane architecture and lateral mobility [47]. Recruitment
of annexin 2 into lipid rafts can stabilize the actin cytoskeleton [39,
48]. Lipid rafts are also known to modify cell adhesion. Cholesterol
enrichment in the plasma membrane has been shown to increase
α5β1 integrin-mediated adhesion to ﬁbronectin [49]. Integrins are
receptors for extracellular matrix proteins and mediate cell adhesion
to ﬁbronectin with the Focal Adhesion Kinase (FAK).
Lipid rafts may provide an important plasma membrane
nanoenvironment in which signals are processed, including central
signals for tumor cell growth, apoptotic signals, and other aggressive
characteristics. Functional and biochemical approaches indicate that
ion channels localize to lipid rafts and that this structure regulates
channel function [13].
3. HER
3.1. Generalities
Human Epidermal growth factor Receptors (HERs) are among the
ﬁrst oncogenes identiﬁed. They are part of the receptor tyrosine kinase
superfamily, divided into 20 different sub-families. Several receptor
tyrosine kinases are proto-oncogenes and are therefore potential
targets for cancer therapy [50,51]. The HER family includes four
homologous receptors: HER1 (Erb-B1, EGFR, Epidermal GrowthFactor Receptor), HER2 (Erb-B2), HER3 (Erb-B3), and HER4 (Erb-B4)
that share high homology of their primary structure (40–45%).
These receptors are transmembrane receptors with a N-terminal
domain bearing the extracellular ligand binding site, a transmembrane
domain and an intracellular C-terminal domain bearing the tyrosine
kinase activity.
In physiological conditions, these receptors are expressed in
many types of tissues of epithelial origin, mesenchymal or neural,
where they play an important role in development, proliferation, differ-
entiation and cellular metabolism [51–53]. HERs are overexpressed or
have activating mutations in many tumor types (Table 1).
HERs are normally expressed on the cell surface in monomeric
forms. Receptor activation requires its dimerization (homo or
hetero-dimerization), following ligand binding.
This dimerization allows phosphorylation of the intracellular kinase
domain at tyrosine residues, thus allowing the recruitment of signaling
molecules and activation of signaling pathways.
The system of homo and hetero-dimerization of HER receptors
confers a high degree of complexity. Moreover, different combinations
of receptors can lead to variable biological responses [54]. EGFR or
HER2 homodimers cause a moderate signal, homodimers of HER3 do
not allow signal transduction. Heterodimers cause a stronger intensity
of signaling pathway than homodimers [55]. Heterodimers containing
HER2, especially HER2–HER3 dimers, are the most active [56].
There are many speciﬁc ligands of HER receptors, which have all
EGF (Epidermal Growth Factor) domain-like which gives them
their binding speciﬁcity [57]. These ligands are divided into three
groups according to their afﬁnity for various receptors: the ﬁrst
group is composed of EGF, amphiregulin and TGFα, which speciﬁcally
bind to EGFR; the afﬁnity of EGF for EGFR can be modulated by the
Table 1
Alteration of HER in cancer. This table describes the genetic alteration of HER in various cancers. This includes ampliﬁcations and mutations. HER: Human Epidermal growth factor
Receptor.
Gene Cancer Genetic alteration References
EGFR (HER1) Breast
Glioblastoma
Non-small cell lung cancer
Cervical carcinomas
Pancreatic
Head and neck
Ampliﬁcation/overexpression
Ampliﬁcation associated with mutation
Mutation or deletion mutation in the kinase domain
Somatic kinase domain mutation
Ampliﬁcation/overexpression
Ampliﬁcation/overexpression
[220]
[221]
[222–225]
[226]
[227]
[228]
HER2/neu Gastric
Endometrial cancer
Non-small cell lung cancer
Breast
Ampliﬁcation/overexpression
Ampliﬁcation/overexpression
Kinase domain mutation
Ampliﬁcation/overexpression
[229]
[78]
[230]
[74,231]
HER3 No genomic level alterations in HER3 found in tumors [55,232]
HER4 Stomach, lung, colon, melanoma and breast Somatic kinase domain mutation [233,234]
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epiregulin form the second group and bind to EGFR and HER4. The last
group consists of neuregulins (1 to 4), which show afﬁnity for HER3 and
HER4 receptors. There is no identiﬁed ligand to HER2 [51,57].
These receptors are profoundly important in human cancer. In par-
ticular, EGFR and HER2 have been implicated in the development
of human cancers [58]. Patients whose tumors have an alteration in
HER receptors are associated with more aggressive disease and poorer
clinical outcome [59]. HER receptors undergo various types of alteration
in human tumors including gene ampliﬁcation, receptor overexpres-
sion, activating mutations, overexpression of receptor ligands and/or
loss of negative regulatory controls [58].
3.1.1. HER1/EGFR
EGFRwas theﬁrst tyrosine kinase receptor characterized [51,53] and
one of the ﬁrst proto-oncogenes identiﬁed [60]. While EGFR has multi-
ple physiological roles in the development of tissues of epithelial origin,
HER2, HER3 and HER4 receptors especially have a role in the develop-
ment of skeletal muscle and nervous tissues [53]. EGFR activation
leads to an increase of cell proliferation and cell mobility, and a decrease
of cell apoptosis. EGFR plays a role in the epithelial–mesenchymal
transition, in the regulation of matrix metalloproteinases and the
angiogenesis growth factor VEGF-A, and probably plays a role in the
maintenance of stem cells [61] as well as in tumor angiogenesis [62].
Clinically, EGFR overexpression is associated with a bad prognosis as
well as an increased of risk of metastatic spread [63,64].
The native EGFR forms homo- or heterodimers, preferably with
HER2 and HER3 [65]. There are two subtypes of EGFR based on their
afﬁnity to EGF: 10% of the EGFR pool has a high afﬁnity to EGF and
90% presents a low afﬁnity [66,67]. The activation of signaling pathways
downstream of EGFR depends on the receptor subtype [66]. The ligand
binding to the receptors with high afﬁnity activates the Ras/Raf/MAPK
and PI3K/Akt pathways whereas ligand binding to the low afﬁnity
receptors results in the activation of STAT (Signal Transducer and
Activator of Transcription) and PLCγ/PKC (Phospholipase Cγ/Protein
kinase C) pathways.
EGFR also has a nuclear function. The nuclear localization of EGFR
is related to poor prognosis in breast, ovary and upper aerodigestive
cancers and may also affect the response of chemo- and targeted
therapies [68–70].
EGFR plays a major role in malignant phenotype acquisition
and tumor progression [71], particularly in regard to colorectal tumori-
genesis. Considering the major importance in oncogenesis and its fre-
quency of overexpression in many types of tumor, this receptor is a
therapeutic target, particularly in colorectal and upper aerodigestive
tract cancers [71,72].
3.1.2. HER2
The HER2 proto-oncogene which was called HER2/neu or (C-)ErbB-2
is overexpressed in 15–20% of breast cancer [73], and its overexpressionis linked to a very aggressive tumor proﬁle [74]. Overexpression of HER2
is also found in gastric [75,76], ovarian [77] and endometrial cancers
[78]. Mutations of this receptor are uncommon in cancer and its overex-
pression seems to be themainmechanismbywhichHER2promotes on-
cogenesis. Inmost cases, HER2 activation happens by gene ampliﬁcation
followed by signiﬁcant overexpression.
In breast cancer it is crucial for both prognosis and prediction of the
response to targeted therapies, and HER2 testing is recommended in all
newly diagnosed cases of invasive breast cancer [79,80]. The introduc-
tion of trastuzumab orHerceptin®, a recombinant humanizedmonoclo-
nal antibody to the extracellular domain of HER2, has dramatically
changed the treatment of HER2-ampliﬁed breast tumors in the adjuvant
and metastatic setting [81,82], and more recently lapatinib, a tyrosine
kinase inhibitor targeting HER1 receptors and HER2 has further
improved therapy [83,84].
3.1.3. HER3
HER3 presents a mutation in its kinase domain (Asn for Asp change
in the catalytic site), which is not functional, and thus can signal only in
the context of receptor heterodimerization [85], usually with HER2.
Binding of Akt at the phosphotyrosine residues of HER3 directly causes
its allosteric activation. HER3 plays a major role in malignant transfor-
mation controlled by HER2, and contributes substantially, in vitro and
in vivo, for cell proliferation and growth of tumors overexpressing
HER2. A loss of HER3 expression in cell lines overexpressing HER2 has
led to an inhibition of cell growth equal to a loss of HER2 function.
In animal models of colorectal tumors, spontaneous deletion of
HER3 prevents tumors [55]. Its role in signal transduction and its role
in resistance anti-EGFR or anti-HER2 therapies, whether or tyrosine ki-
nase inhibitors monoclonal antibodies, are crucial in cancer pathology.
3.1.4. HER4
HER4 has a signiﬁcant sequence homology to EGFR, but its
involvement in human pathology is not yet clearly demonstrated.
HER4 could participate in HER3 sequestration, which could explain
why its expression is a good prognostic factor in early stage breast
cancer [55]. Activating mutations of HER4 are frequently in melanomas
[86]. Its overexpression is not involved in tumorigenesis; HER4 signal-
ing pathway is preferably associated with differentiation, cell death
and decrease of tumorigenicity.
Importantly, cancers that co-overexpress different types of HERhave
a worse outcome than do those that overexpress either receptor alone.
Thus, expression levels of EGFR, HER-2/neu, and HER-3 may help
predict the outcome of patients with oral SCC [87]. In lung cancer
the incidence of co-expression of both EGFR and HER2 was greater
in patients with metastasis than in those without metastasis [88].
3.1.5. Signaling pathways
The frequent activation of HER proteins in many types of human
cancer attests to their crucial role in regulating pathways important
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receptors: the Ras–MAPK, PI3K/Akt, JAK/Stat and PLCγ pathways. The
Ras/Raf/MAPK pathway has a central role in proliferation and survival
cell regulation of a wide spectrum of human tumors. The activation
of Ras causes a cascade of phosphorylation activities: Raf (MAP kinase
kinase kinase), MEK (mitogen-activated extracellular signal regulate
kinase-activating kinase) and ERK (Extracellular Signal Regulated
Kinase). ERK then translocates to the nucleus where it activates
various transcription factors involved in replication and cell cycling [89].
This signaling pathway is widely involved in the phenomena of
resistance to targeted anti-EGFR therapies. For example, the mutation
of KRAS oncogene (Kirsten Rat Sarcoma virus, a protein being situated
downstream EGFR signaling pathway) is frequently observed in various
human tumors and have been implicated in both oncogenesis and
tumor progression. The activation of this pathway in cancer promotes
tumor angiogenesis and development, stimulates cell proliferation and
suppresses apoptosis [90]. This pathway is also involved in metastatic
spread [91,92].
PI3K is a heterodimeric protein with a regulatory subunit, p85, and a
catalytic subunit, p110. The activation of various receptor tyrosine
kinases such as not only EGFR but also Platelet-Derived Growth
Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor (FGFR)
and Insulin-like Growth Factor 1 Receptor (IGF1R) activates the
PI3K following the binding of the p85 regulatory subunit. This binding
causes a conformational change, after which PI3K will catalyze
PIP3 (phosphatidylinositol 3,4,5 triphosphate) formation from PIP2
(phosphatidylinositol 4,5 diphosphate). When bound to PIP3, Akt
will be activated by phosphorylation. The p85 subunit can also bind
to various cytoplasmic proteins such as protein kinase C or Ras,
allowing the interaction between Ras and the p110 catalytic subunit
[92]. When bound to PIP3, Akt will be activated by phosphorylation.
The p85 subunit can also bind to various cytoplasmic proteins such
as protein kinase C or Ras, allowing the interaction between Ras
and the p110 catalytic subunit [92].
Akt activation leads to its membrane recruitment. Akt is activated in
many tumor types, including ovarian (40–70%), pancreatic (60–70%),
lung (30–70%) and thyroid (80–100%) cancers [91]. Akt can be indi-
rectly regulated negatively by P53 and is activated by the loss of func-
tionality of tumor suppressor PTEN (Phosphatase and TENsin homolog
deleted on chromosome ten) and cyclin-dependent kinase inhibitor
1B/p27Kipl. The main function of PTEN is to block the PI3K pathway
by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate
to PI-4,5-bisphosphate thus counteracting PI3K function. It is not
surprising that loss of PTEN function has an important impact on multi-
ple aspects of cancer development such as cell proliferation, apoptosis
resistance, angiogenesis, metabolism regulation, cell migration and
metastasis [93,94].
3.1.6. EGFR and calcium
Among the HER family members, the link to Ca2+ has most
intensively been studied on EGFR, which both induce and are
regulated by Ca2+-signaling. Initially shown to increase cytoplasmic
free Ca2+ of epithelial and ﬁbroblast cell lines [95,96], it was later
shown to release Ca2+ from intracellular stores as well as to promote
the inﬂux of extracellular Ca2+. EGF was found to induce oscillatory
changes in the intracellular Ca2+ concentration and SOCE (see for
review [5] and Fig. 1 of this review). EGFR in its turn can be regulated
both by extracellular and intracellular Ca2+.
Extracellular Ca2+ is the primary ligand for the Ca2+-sensing
receptor (CaSR), a G-protein coupled receptor. Initially cloned from
bovine parathyroid [97], the CaSR was shown responsible for
regulating parathyroid hormone release and thus maintaining
Ca-homeostasis [98,99].
The synthesis of PTHrP in its turn and its secretion are controlled
by the MAP kinase signaling cascade [100], induced by transactivation
of the EGFR by the CaSR. This involves the stimulation of matrixmetalloproteinases induced by G protein/PLCβ, resulting in the release
of membrane-anchored EGFR ligands and consequentially the EGFR
activation [101,102].
Longer exposure to high extracellular Ca2+-concentration induces
proliferation of the MCF7 breast cancer cell, as a further consequence
of MAP kinase activation via the crosstalk between the CaSR and
EGFR [103,104]. This involved the overexpression of the TRPC1 cation
channel, a release of Ca2+ from the endoplasmic reticulum, and conse-
quentially an inﬂux of external Ca through the store-operated TRPC1.
(The impact of TRPC1 to EGFR activities will be discussed further
below). Again, metalloprotease activity, likely for the release of EGFR
ligands, is required to induce this pathway.
Intracellular Ca2+ can inﬂuence the EGFR, by binding to a
juxtamembrane calmodulin (CaM) site [105,106]. The CaM-binding
site of the EGFR is part of the region in juxtaposition to the tyrosine
kinase domain, and iswell conservedwithin the 3 active tyrosine kinase
proteins of the HER family. Binding of CaM at the juxtamembrane site
prevented the phosphorylation of residue Thr-654 by PKC, and con-
versely, phosphorylation of this site by PKC prevented its subsequent
interaction with CaM [107,108]. Structural and kinetic analyses have
shown that this region contributes to activating the EGFR by facilitating
the dimerization of the kinase domains even in the absence of a ligand
[109,110]. Amechanismhas been proposed, forwhich the juxtaposition
domain is postulated to bind electrostatically to the inner leaﬂet of the
plasmamembrane. The binding of CaM neutralizes the positive charges
of the domain, thus facilitating its dissociation from the membrane
and the dimerization of the kinase domains [110]. Consequently, bind-
ing of Ca2+/CaM results in autophosphorylation of the EGFR [111].
Concerning downstream targets of the EGFR activation, calmodulin-
dependent phosphorylation of Akt but not ERK1/2 has been observed
in breast cancer lines [112], which may give rise to the hypothesis
that Ca2+ discriminates between the two major pathways of EGFR
signaling. Consistent with the above-mentioned hypothesis that
the activation of the EGFR by CaM occurs at the plasma membrane,
stimulation with EGF resulted in the translocation of both calmodulin
and Akt to the plasma membrane [112].
3.2. EGFR and lipid rafts
Multiple studies have been performed about the cellular location
of EGFR and the impact to its activity. It is well established that this
receptor is located at the plasma membrane of human normal and
pathological cells and may be translocated to intracellular vesicles
after being activated. In some cases, upon stimulation by his ligand
EGF, phosphorylated EGFR appears in membrane ridges and punctate
structures. These structures have been identiﬁed as lipid rafts and may
contain other phosphorylated proteins, interacting with EGFR for
signaling [113]. EGFR was found either in caveolae [114–117] and in
non-caveolar lipid rafts [118–120]. In all cases, its location in these
two different types of lipid rafts promotes receptor activation, regula-
tion and interaction with other signaling proteins, inducing signaling
transduction such as MAPK and Akt pathways.
As mentioned above, EGFR is concentrated in caveolae in both
normal cells [116] and cancer cells [117], promoting receptor/receptor
interaction and oligomerization. Other proteins like Ras, Raf, Grb2 or
ERK, part of the MAPK activation pathway, localize in caveolae as well
[114,121]. Interestingly, analysis of membrane fractions obtained by
sucrose gradient ultracentrifugation showed that HER2 and Shc-p66
(proteins correlated with the HER2 signal transduction pathway)
were preferentially enriched in lipid rafts together with ganglioside
GM3 and EGFR [122].
The activities of EGFR and other signaling proteins may be attenuat-
ed by their interaction with caveolin, the major protein component of
caveolae. A region in caveolin, called the caveolin scaffolding domain,
has been identiﬁed as responsible for oligomerization and also interacts
with other proteins. It interacts with caveolin binding motifs, which in
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its kinase domain (aa 686–960). This motif is found in other receptor
tyrosine kinases, among which another EGFR family member, HER2,
and their binding to the caveolin scaffolding domain inhibits the kinase
activity [115]. Similarly, ERK and MEK interact with the caveolin
scaffolding domain as well, this interaction inhibiting their activities
[116]. Therefore, EGFR and downstream signaling proteins of the
MAPKpathway localized in caveolae and sequestered in a stable confor-
mation form an inactive signaling complex. Upon stimulation by its
ligand(s), EGFR is activated and detaches from caveolin to promote
the signal transduction. The caveolin-binding motif may regulate the
activity of EGFR, however its localization in the caveolae appears to be
determined by a more N-terminal motif (aa 275–647, containing the
transmembrane region) [124]. It was found that after its activation
EGFR delocalizes from the caveolae. In glioblastoma cells, the release
of EGFR out of the caveolae increases ligand-induced phosphorylation
and is associated with a more invasive phenotype [117]. On the other
hand, it seems that the migration out of caveolae depends on the type
of EGFR activation [124].
A well-known mode of activation is binding of its natural ligand
EGF, leading to receptor homodimerization and heterodimerization,
and phosphorylation of tyrosine residues to activate downstream
signaling pathways [125]. This phosphorylation can also be induced
by transactivation by G protein coupled-receptors (RCPG), which
promote HB-EGF release from the cell surface through a metallopro-
teinase. This mechanism plays an important role in mitogenic signal-
ing and regulation of various ion channels [126]. The EGFR activities
can be downregulated by phosphorylation of Thr 654 by protein
kinase C, which inhibits ligand binding and leads to receptor inter-
nalization [127]. Whereas phosphorylation of at least one tyrosine
residue is needed to delocalize EGFR from the plasma membrane
[124], phosphorylation of Thr 654 prevents the exit from caveolae.
The activation of the EGFR by EGF, its delocalization out of the
caveolae, and the recruitment and disappearance of RAF-1 in the
caveolae fraction occur within minutes and appear highly coordinated
with the limited time of MAPK phosphorylation [124]. The kinetics
of their localization may therefore regulate the time course of the
signal transduction.
Another mechanism to remove active EGFR is by endocytosis,
leading to EGFR degradation. It should be pointed out that this
mechanism appears independent of another regulation of EGFR
activity, its endocytosis and trafﬁcking into endosomes and ﬁnally
degradation in lysosomes [124]. It has also been shown that EGFR
and signaling proteins as Ras, MEK or MAPK initially remain active
in early and later endosomes. It seems that an active complex in
endosomes continues to propagate signal transduction to signaling
pathways before complete degradation [128,129].
The localization of EGFR does not depend on the presence of
caveolin. An immunoﬂuorescence microscopy study visualized
EGFR rather in non-caveolar lipid rafts, which are characterized by
the presence of ganglioside GM1 [118,119]. Other cells do not express
caveolin, such as LNCaP prostate cancer cells, but still possess lipid raft
compartments. In these cells, phosphorylated EGFR is only present in
lipid raft domains, and ligand-induced phosphorylation does not induce
EGFR redistribution. More, this phosphorylated EGFR location in lipid
rafts promotes the Akt1 signaling pathway [33].
Amajor regulator of EGFR appears to be the amount of cholesterol
in the plasma membrane. Several studies have dealt with the inﬂu-
ence of cholesterol to EGFR activity. Disrupting lipid rafts by a
cholesterol-depleting agent, methyl-β-cyclodextrin (MβCD), leads
to an increase of EGFR ligand-independent phosphorylation and
stimulates cell growth [130,131].MβCD-induced EGFR phosphorylation
activates ERK1/2 both by the Ras/Raf/MEK cascade and signaling
through PI3K [132,133].
In contrast, Akt phosphorylation appears to depend on its locali-
zation in non-caveolar lipid rafts. Here, disrupting lipid rafts by twodifferent agents, MβCD and Filipin, a polyene macrolide that binds
cholesterol, decreases EGF-induced Akt1 phosphorylation and the
level of the anti-apoptotic protein, Bcl-Xl. Depending on the cellular
system used, Akt activation may be initiated through the kinase
activity of EGFR [27,33], or more indirectly through Src associated
with EGFR [134].
In summary, lipid rafts (caveolae or non-caveolae) are major
platforms for EGFR regulation. They promote the regulation of
EGFR downstream signaling pathways, MAPK and Akt to lead to
growth and proliferation cell and participate in cell transformation
and malignancy of cancer cells.
4. Ion channels and lipid rafts
4.1. KCa, ClCa and Ca2+ channels
Ca2+-activated K+ channels (KCa) comprise many channels, which
differ in their primary amino acid sequences and exhibit different single
channel conductance and pharmacological proﬁles. Therefore, they
can be divided into three subfamilies: big conductance (BKCa also
named MaxiK or KCa1.1 channel), intermediate conductance (IKCa
also named KCa3.1 or SK4) and small conductance (SKCa also named
KCa2.x channel with SK1/KCa2.1, SK2/KCa2.2 and SK3/KCa2.3
channels). Ca2+ channels comprise Non-Voltage Gated Ca2+ channel
(NVG-Ca2+ channels) with the TRP family (TRPC, TRPV, TRPM, TRPA,
TRPP, TRPML and TRPN), Orai (Orai1 to Orai 3) and their partners
STIM (STIM1 to STIM2) and voltage gated Ca2+ channels (VG-Ca2+
channels) with T-type, L-type, N-type, P/Q-type and R-type Ca2+
channels. The molecular nature of Ca2+-activated Cl− channels (ClCa)
has been uncertain, but recently a new gene family, TMEM16
(anoctamin), has been identiﬁed. There is strong evidence that
TMEM16A (anoctamin 1; Ano 1) produces ClCa currents with kinetics
similar to native ClCa. Interestingly, ANO1 overexpression has been
considered as a potential marker for distant metastasis and was found
to regulate cancer cell migration and proliferation [9].
If in a physiological context, KCa, ClCa and Ca2+ channels regulate
neuronal and smooth muscle excitabilities. This is not observed in a
tumor context where the physiological function of these channels is
hijacked by cancer cell to drive essential biological functions for tumor
development such as cell proliferation and cell migration [6–10].
Table 2 summarizes some of these channels found in cancer cells and
their biological role in cancer cells. Ca2+ is ubiquitous and regulates
through Ca2+ channels several pathways in stroma and cancer cells.
In glioma cells, TRPC1 has been correlated with EGF-mediated direc-
tional migration. In particular EGF-mediated chemotactic migration is
lost when TRPC channels are inhibited pharmacologically and reduced
when the expression of TRPC1 is compromised through shRNA knock-
down. Interestingly, TRPC1 channels localize to the leading edge of
migrating glioma cells where they co-localize with markers of caveolar
lipid rafts. This raft association appears important since disruption
of lipid rafts by depletion of cholesterol impaired TRPC1 channel-
mediated Ca2+ entry and EGF mediated chemotaxis [135].
In prostate cells, migration is controlled by several TRP channels.
Pigozzi et al. [136] show that store depletion modulates the expression
of TRP (C1, C3 and V6) proteins involved in the agonist-induced inﬂux
of Ca2+. For TRPV2, an expression is underlined in aggressive prostate
and bladder cancer cells and tissue samples inwhich its activation stim-
ulates the migration and invasive phenotype of these cells [137,138].
Cancer cell proliferation is modulated by TRP channels. TRPM2-
knockdown inhibits the proliferation of the prostate cancer cell line
BPH-1 [139]. TRPM7 is known to play an important role in breast
cancer cell migration, invasion and, in fact, in metastasis development
[140–142]. Actually, the TRPV sub-family appears like a high modulator
of colorectal cell proliferation and migration [140,143–145].
Themajor Ca2+ entry pathway in non-excitable cells in general, and
cancer cells in particular, is provided by SOC (Store Operated Channels),
Table 2
Expression and biological roles of some ion channels in cancer. BKCa/KCa1.1: Big conductance Ca2+-activatedK+ channels, IKCa/KCa3.1/SK4: Intermediate conductance Ca2+-activatedK+
channels, SK3/KCa2.3: small conductance Ca2+-activated K+ channel, ClCa: Ca2+-activated Cl− channels, Ano1/TMEM16A: anoctamin 1, T-type VG-Ca2+ channels: T-type Voltage-Gated
Ca2+ channels, TRPx: Non-Voltage-Gated Ca2+ channels Transient Receptor Potential; Orai: Non-Voltage-Gated Ca2+ channels Orai, STIM: Stromal interaction molecule.
Protein Gene Cancer Biological roles References
KCa1.1/BKCa KCNMA1 Glioma and neurons Migration
Apoptosis
Permeability of blood–brain tumor
[235–239]
KCa2.3/SK3 KCNN3 Breast
Melanoma
Colon
Migration
Therapeutics
[155,240,241]
IKCa/KCa3.1
SK4
KCNN4 Glioma
Colon
Prostate
Breast
Vascular smooth muscle
Migration
Apoptosis
Proliferation
Therapeutics
[156,240,242–247]
CaCC-1, hCLCA1 CLCA1 Melanoma
Lung
Colon
Breast
Migration
Pulmonary metastasis Proliferation
Cell volume
Pro-apoptosis
[149,248–250]
ANO1, TMEM16A ANO1 Prostate
Breast
Bladder
Pancreas
HNSCC
ESCC
GIST
Proliferation
Invasion
Migration
Metastasis progression
Tumor promoting factor
Predictive marker
[63,150–154,251]
hCLCA3 CLCA3 Spleen Non-pore function [252]
ClC-3 CLCN3 Glioma Migration [158]
T-type VG-Ca2+ channels CaV3.2 Prostate SOCE modulation
Cancer cell growth
[253,254]
TRPC1 TRPC1 Glioblastoma
Kidney
Pancreas
Prostate
Lung
Breast
Migration
Chemotaxism, stretch activation
Motility, invasion
SOC formation
Proliferation
Proliferation
[135,136,140,255–258]
TRPC2 TRPC2 Thyroid Decrease cell migration (via Rac) [259]
TRPC3 TRPC3 Prostate
Lung
Breast
Ovarian
SOC formation
(via α-adrenergic stimulation)
Prognostic marker, proliferation
Migration, invasion
Proliferation
[136,148,258,260,261]
TRPC4 TRPC4 Lung Proliferation [258]
TRPC6 TRPC6 Lung
Breast
HNSCC
Glioblastoma
Proliferation
ER expression, lymph node metastasis
Invasion
Migration, invasion
[258,262–264]
TRPV1 TRPV1 Bladder
Urogenital tractus
Hepatoblastoma
Prognostic marker
Migration
[265]
[266]
TRPV2 TRPV2 Prostate
Urothelial carcinoma
Glioma
Migration
Migration, invasion
Proliferation
[137,138,267,268]
TRPV4 TRPV4 Hepatoblastoma Migration [266]
TRPV6 TRPV6 Breast
Colon
Prostate
Invasion, proliferation, migration
Proliferation
Proliferation, SOC formation
[33,136,140,143–145]
TRPM1 TRPM1 Melanoma Modulation migratory potential
Metastasis reduction
[269]
TRPM2 TRPM2 Pancreas
Prostate
Migration
Proliferation
[139,270]
TRPM7 TRPM7 Breast
Neuroblastoma cells
Pancreas
Nasopharyngeal carcinoma
Lung
Proliferation, migration, invasion,
metastasis progression
Cell spreading
Migration
Migration
Migration
[140–142,255,271–275]
TRPM8 TRPM8 Oral squamous carcinoma
Prostate
Neuroblastoma
Melanoma
Pancreas
Glioblastoma
Invasion
Androgen receptor requirement,
thermosensitivity, reduction of adhesion
Sensor of extreme condition
Apoptosis activation
Proliferation
Migration through BK activation
[276–283]
Orai1 Orai1 Breast Migration
Therapeutics
[155]
(continued on next page)
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Table 2 (continued)
Protein Gene Cancer Biological roles References
Orai1/STIM1 Orai1
STIM1
Breast
Glioblastoma
Hepatocellular carcinoma (HCC)
Cervical cancer
Migration, invasion
Migration
Migration, invasion
Cancer growth, migration, angiogenesis
[146,148,157,284,285]
Orai3/STIM1 Orai3
STIM1
Breast Tumorigenesis, invasion [147,286]
2610 M. Guéguinou et al. / Biochimica et Biophysica Acta 1848 (2015) 2603–2620which require STIM1, Orai1 and Orai3 to function in cancer cells.
Orai1/STIM1 or Orai3/STIM1 complex is implicated in breast, cervical
and glioblastoma multiform tumor cell migration in vitro and in a
mouse model of metastases generated by tumor xenografts [146–148].
hCLCA1 was found to regulate the migration of B16–F10 cells and
lungmetastasis development inmelanoma [149]. Furthermore, another
member of CLCA family, ANO1, plays important roles in cancer progres-
sion. Liu et al. provide compelling evidence that upregulation of ANO1 is
involved in the proliferation, progression and pathogenesis of metasta-
tic prostate cancer [150]. In other cancers, the role of ANO1 is unknown
but different variants of expression (short version, in plasma or nuclear
membrane etc.) were found in patients' tissues [9,151,152]. ANO1
should promote breast cancer progression by activating EGFR and
CaMK signaling [153] or induce an activation of MAPK pathway [154].Ca2+ acvated K+ Channels
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Fig. 2. Proposed models to explain intracellular Ca2+ and membrane potential variations tha
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Ca2+ oscillation (3). B)While the association of KCa or ClCawith voltage gated Ca2+ channels (
membrane potential variation is opposite. Em; membrane potential, [Ca2+]; intracellular Ca2+4.2. Complexes of KCa/ClCa/Ca2+ channels
During the last decade, KCa, Ca2+ channels and ClCa channels were
found to be expressed in various cancers.Wehave already reviewed stud-
ies that present evidence of the complex formation between KCa and
Ca2+ channels and their potential involvement in cancer [11]. Brieﬂy,
the association of Orai1 andK+ channels shown to be involved in control-
ling cancer cellmigration: SK3 associateswithOrai1 in theMDA-MB-435s
cell line within lipid rafts [155]. Such association between KCa and Ca2+
channels has also been observed between BKCa-Cav3.2, IKCa-TRPV6
[156] and the Human Ether-a-go-go potassium Channel 1 (hEag1) with
Orai1 [157]. Recent data suggested that such complexes could also be
found between ClCa and Ca2+ channels [158]. Considering that the equi-
librium potential for Cl− is usually found to bemore positive than for K+,3
Em (mV)
0
- 20
- 80
[Ca2+] (nM)
100
400
Kca - NVG Ca2+
complex activation
- 40
ClCa - NVG Ca2+
complex activation
1 2
KCa- ClCa - NVG Ca2+
complex activation
Em (mV)
0
- 20
- 80
[Ca2+] (nM)
100
400
- 40
ClCa- VG Ca2+
complex activation
Kca- VG Ca2+
complex activation
3
KCa- ClCa - VG Ca2+
complex activation
21
Time
t would be expected in cancer cells. A) Association of Non-Voltage Gated Ca2+ channels
lCa has an opposite effect (2). Association of KCa and ClCawith NVG Ca2+ should generate
VG Ca2+) leads to the same Ca2+ oscillation (3) than with NVG Ca2+ channel, the effect on
concentration.
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ClCa channels. Fig. 2 proposes how these complexes, KCa–Ca2+ channels
and ClCa–Ca2+ channels, could regulate Ca2+ entries via a regulation of
membrane potential.
Non-VoltageGated Ca2+ channels (NVG-Ca2+ channels) are activated
following Ca2+ RE empty (SOCs), receptor activation (ROCs) or are
constitutively active. The increase of intracellular Ca2+ concentration
that occurs through NVG-Ca2+ channels activates KCa channels. KCa
activation by hyperpolarizing plasma membrane and by increasing the
Ca2+ driving force favors Ca2+ entry through NVG-Ca2+ channels
and in turn increases intracellular Ca2+ concentration. This is what
is expected in non-excitable cells, such as epithelial/endothelial
cells, in which KCa–NVG-Ca2+ complexes play a crucial role in a
low-energy cost and positive feedback loop. In the opposite if Ca2+
through NVG-Ca2+ channels activates ClCa channels this would
repolarize (if the membrane has been hyperpolarized) the plasma
membrane, and by reducing the Ca2+ driving force would decrease
the intracellular Ca2+ concentration of non-excitable cells. Thus if
KCa–NVG-Ca2+ and ClCa–NVG-Ca2+ complexes are found in the same
cell, intracellular Ca2+ concentration variations would be expected
withmembrane potential variations (Fig. 2). A depolarization is needed
to activate voltage-gated Ca2+ channels (VG-Ca2+ channels). Note
that a constitutive Ca2+ entry can also be observed when there is an
overlap between the activation and inactivation curves of VG-Ca2+
channels (Ca2+ window current). The increase of intracellular Ca2+
concentration through VG-Ca2+ channels activates KCa channels.
By regulating the membrane potential (repolarization) this would
decrease intracellular Ca2+ concentration in excitable cells, such as
neurons or smooth muscle cells. Indeed, KCa activation induces a
repolarization or a hyperpolarization that closes VG-Ca2+ channels,
thereby decreasing intracellular Ca2+ entry through VG-Ca2+ channels.
In this case KCa channels play a crucial role in this negative feedback
loop. In contrast, if Ca2+ entry activates ClCa channels, this would de-
polarize the plasma membrane, and by activating VG-Ca2+ channels
this would increase Ca2+ entry through these channels. Thus if
KCa–VG-Ca2+ and ClCa–NVG-Ca2+ complexes are found in the same
cell, intracellular Ca2+ concentration variations would be expected
with membrane potential changes (Fig. 2).
4.3. Lipid raft ion channel complexes
4.3.1. Lipid raft KCa/ClCa/Ca2+ complexes
BKCa (also named KCa1.1) channels have been shown to be located
in the caveolar lipid raft domains [159–164]. Many studies have
suggested that in non-excitable cells such as endothelial cells, Cav1
serves as scaffold to sequester the channel in the plasma membrane
region in an inactive state [160,165]. The activation of BKCa current
upon isoprenalin stimulation did not perturb channel localization in
the plasma membrane, demonstrating that BKCa does not need to be
redistributed from caveolae to non-lipid raft domains to be in its activa-
tion state [160]. It has been suggested that caveolae targeting control
“dormant” BKCa channels that are positioned in the vicinity of impor-
tant signaling molecules, allow tight and efﬁcient channel activation
upon stimulation by agonists or other signals. Since BKCa has also
been found to co-localize with Cav1 in cancer cells, deregulation of
many signaling pathways could explain why BKCa activity is not
inhibited in resting condition [161,163]. Weaver et al. demonstrated
that the IP3 receptor/channel was the Ca2+ source for BKCa activation
in glioma cells (Fig. 3). While BKCa channels do not interact directly
with IP3R, they are jointly localized in microdomains of lipid rafts
on the lamellipodia of glioma cells, which provide the propulsion to
migratory cells. Multiple growth factor receptors located into lipid
raft domains are able to stimulate IP3-mediated release of Ca2+ and to
activate K+ ﬂuxes required for cell migration [161]. BKCa blockers also
reduced cancer cell proliferation. In breast cancer cell lines a study has
shown a physical interaction between BKCa and IP3R3 in lipid raftdomains. ATP increased MCF-7 cell proliferation and this effect was im-
paired when the expression of BKCa and/or IP3R3 was knocked-down.
Interestingly, in the non-cancer breast cell line MCF-10A, a physical in-
teraction between the channel and IP3R has not been found and neither
ATP application nor BKCa silencing affected cell proliferation [166]. An
alternative way of activating BKCa was found in the cancer prostate
cell line LNCaP: the presence of auxiliary protein γ subunits opens
BKCa at resting membrane potential and by low intracellular Ca2+
[167,168]. The localization and the role of these BKCa auxiliary proteins
in lipid rafts have to be determined in cancer and non-cancer cells.
In vascular endothelial cells SK3 (also named KCa2.3) is exclusively
located in lipid raft domains and spatially associated with caveolin
(Fig. 3). Depletion of cholesterol by MβCD treatment reduced SK3-
mediated hyperpolarization and cholesterol supplementation reversed
this effect, suggesting that SK3 location in caveolar lipid raft domains
is critical to channel function in endothelial cells [169,170]. We there-
fore hypothesize that caveolar lipid raft domains maximize the control
of channel function by a nearby Ca2+ source (receptor or Ca2+ channel)
and proteins regulating its activity (kinases, receptors, etc.). In HEK293T
over-expressing SK3, Gao et al. demonstrated that the channel is located
in lipid raft domains and endocytosed in caveolae in a dynamin-
dependentmanner. SK3 is rapidly retrieved from the plasmamembrane
and enters a recycling compartment fromwhich the channel is returned
to the plasma membrane with a time constant of approximatively
5 min. In the same way, deletion of Cav1 increases the level of
IKCa/KCa3.1 in the cell surface of MEF cells [171]. However, depletion
of cholesterol with MβCD reduces SK3 currents (Maxime Gueguinou
and Yann Fourbon personal communication).
In breast cancer cells we found SK3 to be exclusively located in lipid
raft domains and forming a complex with Orai1. Orai1 is the Ca2+
source for SK3 activity. The SK3–Orai1 complex elicited constitutive
Ca2+ signaling that promotes cancer cell migration and bone metasta-
ses [155] (Fig. 3). We have shown that the activation of the cAMP–
PKA pathway induced a phosphorylation of SK3 channel that reduced
its activity without its displacement from lipid rafts but leads to a
delocalization of Orai1 channel into non-lipid raft domains. This de-
creased the SK3-dependent constitutive Ca2+ entry and SK3-dependent
cancer cell migration [172]. The molecular mechanism involved in the
delocalization of Orai1 remains to be elucidated but one hypothesis is
that PKA activation may reduce the interactions between SK3 and Orai1
channels probably through PKA phosphorylation of SK3.
IKCa (also named KCa3.1 or SK4) is co-expressed with SK3 in
vascular endothelium cells where they play a key role in the endothelial
derived hyperpolarizing factor response. Surprisingly and unlike SK3,
IKCa has been shown to be exclusively located in non-lipid raft domains
(Fig. 3), not associated with Cav1. Therefore, disrupting lipid rafts with
MβCD did not affect IKCa-mediated hyperpolarization in endothelial
cells [170]. Arthur et al. demonstrated that CaSR was co-located with
IKCa into non-lipid raft domains and served as a Ca2+ source [169]
(Fig. 3). The different localizations of SK3 and IKCa could explain the
distinct physiological roles of these channels in vascular endothelia.
IKCa localization was also studied in a hepatoma cell line where it was
localized into non-lipid raft domains in resting cells. Upon cell swelling
IKCa moved transiently into lipid raft domains which was followed
by volume recovery [173]. The authors suggested that cell swelling
may lead to recruitment of a group of proteins including IKCa to the
lipid rafts, and that Ca2+ signaling would contribute to the formation
of a volume recovery complex that coordinates ﬂuid efﬂux with the
restoration of an organized actin cytoskeleton.
Surprisingly, it has not yet been investigated whether SK1 (KCa2.1)
and SK2 (KCa2.2) channels are expressed into lipid rafts and/or
non-lipid raft domains.
4.3.2. Lipid raft/TRPC1 complexes
In non-cancerous cells, TRPC1 has been shown to be distributed in
both lipid raft domains and non-lipid raft domains [174–177]. To our
Fig. 3. Currently describe lipid raft ion channel complexes in cancer cells. Localization of KCa, ClCa, and Ca2+ channels as channel complexes in lipid raft domains hijacks the
biological role of these channels during tumor cell transformation. ROCE: Receptor Operated Ca2+ entry, SOCE: store operated Ca2+ entry, CaSR: Ca2+ Sensing Receptor,
EGFR: Epidermal Growth Factor Receptor, IP3R: IP3 Receptor, BKCa/KCa1.1: Big conductance Ca2+-activated K+ channels, IKCa/KCa3.1/SK4: Intermediate conductance Ca2+-activated
K+ channels, SK3/KCa2.3: small conductance Ca2+-activated K+ channel, ClCa: Ca2+-activated Cl− channels, TRPx: Non-Voltage-Gated Ca2+ channels Transient Receptor Potential;
Orai: Non-Voltage-Gated Ca2+ channels Orai, STIM: Stromal interaction molecule.
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cancer cells: in a leukemia cell line and in epithelial breast and colon
cell lines, TRPC1was found to be only detected in non-lipid raft domains
([178], personal data), whereas in a glioma cell line TRPC1 was
exclusively located into lipid raft domains [135] (Fig. 3).
TRPC1 alone or associated with other channels (Orai1, others TRP)
controls SOCE activated by STIM1 or a non-selective receptor-operated
Ca2+ entry (ROCE) cation channels that are activated by Gq/Gi-PLC
signaling pathway. Accumulating evidence has indicated that the TRPC1
channelosome responsible for SOCE is located in caveolar lipid raft
domains while TRPC1 channelosome responsible for ROCE is located
outside of lipid raft domains [12,177,179] (Fig. 3). A schematic model is
illustrated in the paper of Liao et al. [180].
The TRPC1 location in caveolar lipid raft domains is dependent of
its interaction with Cav1 [181]. Destabilization of the caveolar lipid
raft domains by MβCD treatment or deletion of Cav1 prevents SOCE
[174–176,179,181]. TRPC1–STIM1–Orai1 channelosome regulates
SOCE in several cell types [182]. A study with cav1 gene knockout
showed a disruption of this ternary complex [183]. Recruitment
of TRPC1 in caveolar lipid raft domains is dynamic following Ca2+
store depletion: TRPC1 expression is increased only in lipid raft
domains and is found to be associated with STIM1 aggregated in
the ER/PM junctional domains [177,179]. Recent studies showed
that Cav1 serves as scaffold to sequester the channel in an inactivestate. Following stimulation (Ca2+ store depletion) TRPC1 dissociates
from Cav1 and binds to STIM1, which also results in the activation of
TRPC1-SOC channelosome [184,185]. For additional information on
this topic, we would direct the reader to an extensive recent review
by Ong and colleagues [12].
The TRPC1-ROC channelosome has been localized in the non-lipid
raft domains of HEK293T cells over-expressing TRPC1 with or without
STIM1. Without over-expression of STIM1, TRPC1 are localized in lipid
raft domains and in non-lipid raft domains. The over-expression of
STIM1 imported TRPC1 into lipid raft domains and gradually converted
TRPC1 from a receptor-operated to a store-operated channel. In addi-
tion, cholesterol depletion increases agonist-stimulated currents by
90% [179]. In the same way, receptors coupled to ROC could be located
into non-lipid raft domains as CaSR or α7AChR [169,186].
Since Orai1 channels contribute to form TRPC1-SOC and -ROC
channelosomes, one may speculate that Orai1 could be present in both
lipid raft domains and non-lipid raft domains (Fig. 3). Unfortunately
no data are available to validate this hypothesis. In addition, IP3R after
its activation by IP3 may activate TRPC1 after its conformational
coupling to TRPC1 deﬁning a TRPC1-encoded IP3-ROC [187] (Fig. 3).
4.3.3. Lipid raft/ClCa complexes
In the glioma cell lineD54MG, TRPC1 channels localize to the leading
edge of migrating cells in lipid raft domains, where its expression has
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TRPC1 co-localizes with the chloride channel ClC-3 in caveolar lipid raft
domains of this cell line [188]. The authors have shown that knocking
down TRPC1 inhibited Cl− currents in a Ca2+-dependent fashion,
placing Cl− channels under the regulation of Ca2+ entry via TRPC1.
Interestingly, inhibition of ClC3 or TRPC activity reduced EGF-induced
migration, suggesting that ClC-3 activity under the dependence of
SOCE mediated by TRPC1 promotes glioma migration by facilitating
volume and shape changes [158].
5. Modiﬁcation of the lipid rafts by lipids: a novel strategy to reduce
tumor development?
Omega-3 polyunsaturated fatty acids (n−3 PUFA) enriched in
ﬁsh oils have been demonstrated to interfere with the development
of breast cancer through a number of mechanisms involving non-
cancer – tumor vascularization – or cancer cells. One hypothesis to
explain the mechanism of action of these lipids is the modiﬁcation
of membrane organization/composition, resulting in altered cell sig-
naling and biological function in response to uptake of DHA/EPA
(docosahexaenoic/eicosapentaenoic acids) into phospholipids of plas-
ma membrane and of lipid rafts [189]. n−3 PUFA were found to
enhance the clustering of lipid rafts to form large raft domain that im-
pair lipid rafts' biological functions such as T-cell activation [190,191].
The lipid composition of lipid rafts can be altered by n−3 PUFA.
Indeed, diet-enriched n−3 PUFA were found to reduce cholesterol,
sphingolipid and sphingomyelin lipid raft content [192–194].
As mentioned lipid rafts are required for efﬁcient EGFR signaling. It
was reported that n−3 PUFA could alter the localization and signaling
of EGFR. Indeed, DHA and EPA were found to decrease the lipid raftFig. 4. Lipids as modiﬁers of lipid raft ion channel complexes in cancer cells. The disorganizat
hijacking of KCa/ClCa/Ca2+ complexes during tumor cell transformation. SK3/KCa2.3: small con
Growth Factor Receptor, TRPx: Non-Voltage-Gated Ca2+ channels Transient Receptor Potentiacontent of sphingomyelin, cholesterol, and diacylglycerol in lipid rafts.
They also decreased EGFR levels in lipid rafts. These lipids were also
found to increase the phosphorylation of EGFR and of p38 mitogen-
activated protein kinase (p38MAPK), while GTP-bound Ras and phos-
phorylated extracellular signal-regulated p42/44 MAPK [195,196]
were downregulated. Interestingly, DHA also antagonized the EGFR sig-
naling capacity by increasing receptor internalization and degradation
[197]. Turk and Chapkin reported that in mouse colonocytes n−3
PUFA perturbed various EGF-lipid raft signals such as activation of
H-Ras, ERK1/2, STAT3 and mTOR [189] (Fig. 4). In prostate cancer
cells, DHA induces apoptosis and autophagy via mitochondrial ROS-
mediated Akt–mTOR signaling in prostate cancer cells [198] and
affects the localization and signaling of PIP3/Akt [199]. An inhibition
of constitutive Akt phosphorylation by DHA was also observed in the
MDA-MB-453 cancer cell line [200].
Conjugated linoleic acid, a polyunsaturated omega-6 fatty acid de-
rived from linoleic acid, was also found to alter the lipid composition
of caveolae and the expression of caveolin-1 in the human breast cancer
cell line MCF-7 [201]. Conjugated linoleic acid (Delta9cis,11trans-18:2
being the major isomer) incorporated into caveolae which are
enriched in phospholipids and decreased the localization of caveolin-1
to caveolae [201].
Cholesterol has been known to be greatly increased in cancer cells
and in the surrounding tissues, compared to normal tissues which
the transformed cells derive from [202,203]. Proliferating tumor cells
require more cholesterol than normal cells [204,205]. In this regard,
alterations in cholesterol regulation have been detected in a wide
number of solid and hematological cancers [203,205]. Cancer cells
have been reported to show enhanced endogenous cholesterol
biosynthesis, increased cholesterol acyltransferase enzyme activity,ion of lipid rafts by speciﬁc lipids such as alkyl-lipids is a possible way to counteract the
ductance Ca2+-activated K+ channel, ClCa: Ca2+-activated Cl− channels, EGFR: Epidermal
l; Orai: Non-Voltage-Gated Ca2+ channels Orai.
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However, it remains unknown whether cholesterol accumulation
in transformed tissues promotes cancer appearance, or whether it is a
consequence of the neoplastic transformation. Only epidemiological
studies revealed that the use of statins is associatedwith the prevention
of prostate and kidney cancers, thus suggesting that cholesterol
accumulation contributes to the appearance of a malignant neoplasm
[204,206,207].
Interestingly, 7-ketocholesterol, a component of oxidized LDL,
incorporates into lipid rafts of THP-1 monocytic cells and increased
intracellular Ca2+ by the translocation of TRPC1 to lipid rafts. This in-
duced apoptosis of THP-1monocytic cells [178]. This particular localiza-
tion of Ca2+ channels in lipid rafts would regulate precise and distinct
intracellular Ca2+ changes (amplitude, duration) and thus be important
in the regulation of cellular functions such as cell migration.
n−3 PUFA are not the only lipids that modulate lipid rafts. Alkyl-
lipids are other lipids known to modulate lipid rafts and signaling
pathways. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-
phosphocholine), a synthetic alkyl-lysophospholipids, has been
found to disturb the sphingomyelin–cholesterol model membrane
system in a cholesterol-dependent way [208]. Furthermore, cell
experiments showed that edelfosine colocalizes in vivo with lipid rafts
and that it may reach concentrations higher than 20% (mol/mol) of
total lipid [209]. Edelfosine and perifosine, another synthetic alkyl-
lysophospholipids, induce selective apoptosis in multiple myeloma by
recruitment of CD95 death receptor, Fas-associated death domain-
containing protein, and procaspase-8 into lipid rafts [210] (Fig. 4).
Interestingly, edelfosine treatment also induced a redistribution of
lipid rafts from the plasma membrane to mitochondria, suggesting a
raft-mediated link between plasma membrane and mitochondria [42].
On the basis of the biochemical nature of lipid rafts it has been
suggested that they participate in a series of intracellular functions
such as cell death program [211–213]. Mitochondria are a possible tar-
get for raft components, and raft-likemicrodomainsmay be involved in
themitochondrial remodeling leading to apoptosis and Ca2+ regulation
[214]. A dynamic interplay among plasma membrane and intracellular
organelles and between intracellular organelles occurs at speciﬁc
membrane parts where two membranes come in close apposition
but do not fuse. Thus far, the most studied are the mitochondria-
associated endoplasmic reticulummembrane (MAM). MAM is a spe-
cialized subdomain of the endoplasmic reticulum (ER) membrane
that regulates ER–mitochondria communications. It has a unique
lipid proﬁle and a unique set of proteins involved in Ca2+ signaling
[214]. The accumulation of the glycosphingolipid GM1 at the ER
membranes promotes the juxtaposition of ER and mitochondria at
the MAMs, and in turn increases Ca2+ transfer between these organ-
elles [215]. Thus the modiﬁcation of the composition of lipid of MAM
could regulate ER-to-mitochondria communication and may open a
new avenue in cancer treatment by lipids.
Edelfosine was also found to modulate SK3 channel activity and
cancer cell migration [216]. Edelfosine had no effect on IKCa/SK4,
a channel known to be expressed outside lipid rafts [170] in contrast
to SK3 that was found to be in lipid rafts [155]. These data suggest
that this lipid is acting on SK3 channel by its integration into lipid rafts
(Fig. 4). Interestingly, edelfosine, miltefosine (hexadecylphosphocholine)
and perifosine (octadecyl-(N,N-dimethyl-piperidino-4-yl)-phosphate)
inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway
[217]. Thismay explain the radiosensitization of squamous cell carcinoma
by perifosine [218]. Synthetic alkyl-lysophospholipids also inhibit the
non-vesicular transport of cholesterol from the plasma membrane
to the endoplasmic reticulum and consequently inhibit cholesterol ester-
iﬁcation [219]. This causes a deregulation of cholesterol homeostasis and
accumulation of free cholesterol in lipid rafts of the cell membrane [219].
We have recently demonstrated that Orai1, a NVG-Ca2+ channel
is associated to the SK3 channel and forms a complex in lipid rafts
[155]. In vivo and in vitro data showed that this complex controls aconstitutive Ca2+ entry, cancer cell migration and bone metastases.
Interestingly, we established that in a breast cancer animal model the
alkyl-lipid Ohmline (1-O-hexadecyl-2-O-methyl-sn-glycero-3-lactose)
could block constitutive Ca2+ entry, cancer cell migration and bone
metastases (Fig. 4). This is the ﬁrst report documenting that the dereg-
ulation of an ion channel complex by a synthetic lipid could inﬂuence
metastases. The formation of SK3–Orai1 complex is a gain of a new
biological function, not existing from individual protein or when the
complex is not integrated into lipid-rafts.6. Conclusion
In this review we focused on the lipid rafts KCa/ClCa/Ca2+ channel
complexes that regulate Ca2+ signaling and EGFR signaling in cancer
cells. There is now evidence that KCa, ClCa and Ca2+ channels, alone
or associated in complexes in lipid raft microdomains, play important
roles in the proliferation and migration of cancer cells, crucial for
tumor development. In parallel, lipid rafts are required for efﬁcient
HER signaling and the activation of HER generates intracellular
Ca2+ variations which by the formation of the Ca2+/CaM complex
also control HER. This suggests that lipid rafts organize HER, KCa,
ClCa and Ca2+ channels to regulate intracellular Ca2+ signaling
pathways that regulate cell proliferation, apoptosis and cell migration.
Ion channel lipid raft organization ﬂuctuates between tumor and non-
tumor cells. For example, the Orai1 channel that was not found in
non-tumor cells, moved into caveolar lipid rafts when SK3 channel
was expressed. This forms a speciﬁc channel complex expressed in
epithelial breast cancer cells that promotes a constitutive Ca2+ entry
in cancer cells and may be a target for anticancer drugs. This suggests
that, to evolve, cancer cell could take advantage of the association and
retargeting of two ion channels in lipid rafts.
In addition, lipid components of rafts also ﬂuctuate in cancer
with impact on the biology of cancer cells. It is conceivable that the
presence/abundance of some lipids such as alkyl-lipids in tumor cell
membranesmodiﬁesHER, KCa, ClCa and Ca2+ channel signaling located
to tumor lipid rafts. The precise composition of alkyl-lipids in lipid rafts
needs to be determined in tumor and non-tumor cells. Since the dereg-
ulation of SK3–Orai1 complex by a synthetic lipid that integrated specif-
ically in lipid rafts may inﬂuence metastases, this gives an opportunity
to therapists to address cancer spread by altering the lipid composition
of the lipid rafts.
The discovery of the role of lipids in the biology of tumor cells
leading to HER, KCa, ClCa and Ca2+ channel tumor growth and me-
tastasis development should lead to further research with a focus
on lipids that modulate lipid rafts as a potential attractive strategy
to reduce/prevent tumor development.Acknowledgements
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